國家知識產權局:已有逾1.6萬件元宇宙商標申請 嚴打蹭熱點等惡意註冊
隨著「元宇宙」概念持續走熱,包括騰訊(00700.HK)、小紅書、愛奇藝(IQ.US)等企業正嘗試申請「元宇宙」相關商標,然而申請均遭到駁回。國家知識產權局表示,截至目前,在商標數據庫中約有逾1.6萬件「元宇宙」及「METAVERSE」相關商標申請。該局依據《商標法》及其有關條例規定,依法對「元宇宙」及「METAVERSE」相關商標註冊申請予以審查。
國家知識產權局還指出,堅決反對及嚴厲打擊「蹭熱點」和不以使用為目的囤積等商標惡意註冊行為。相關市場主體在申請註冊商標時,應符合《商標法》有關規定,遵守誠實信用原則,不得損害社會公共利益、擾亂商標註冊秩序。(ta/w) ~
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.